BRIEF-Macrogenics Announces Pausing Of Enrollment Of New Study Participants In Linnet Trial

MacroGenics, Inc. +5.86%

MacroGenics, Inc.

MGNX

3.07

+5.86%

Feb 23 (Reuters) - MacroGenics Inc MGNX.O:

  • MACROGENICS ANNOUNCES PAUSING OF ENROLLMENT OF NEW STUDY PARTICIPANTS IN LINNET TRIAL

  • MACROGENICS INC: U. S. FOOD AND DRUG ADMINISTRATION (FDA) HAS PLACED A PARTIAL CLINICAL HOLD ON ITS PHASE 2 LINNET STUDY OF LORIGERLIMAB

  • MACROGENICS INC: CURRENT STUDY PARTICIPANTS MAY CONTINUE TO RECEIVE STUDY DRUG

  • MACROGENICS: FDA'S PARTIAL CLINICAL HOLD INITIATED AFTER CO'S NOTIFICATION TO FDA OF TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL

  • MACROGENICS: TEMPORARY PAUSE IN ENROLLMENT OF NEW PARTICIPANTS IN LINNET TRIAL DUE TO OCCURRENCE OF RECENT SAFETY EVENTS

Source text: ID:nGNX7pFkgg

Further company coverage: MGNX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.